Illumina CSO Bentley Paints A Vision For The Future Of Precision Medicine
Sequencing A Whole Human Genome Is A Specialist Endeavor
Genomic medicine is coming of age. For Illumina chief scientific officer David Bentley, that not only means improved technology, accuracy and coverage of gene sequencing and a broadening into cancer, but also a better understanding among the wider population of disease and precisely the benefits that gene sequencing can bring to patients – actual and pre-symptomatic.
